Skip to main content

BridgeBio Pharma, Inc.

corporate_fare Company Profile

BridgeBio Pharma, Inc.

BBIO·NASDAQ·Life Sciences·CIK 0001743881

BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with genetic diseases. The company aims to translate advances in genetic science into therapies for patient populations with significant unmet medical needs. Since its founding 10 years ago, BridgeBio Pharma has advanced multiple programs from discovery through regulatory approval and commercialization. To date, more than 8,500 patients have been treated with its approved medicines, and the company has obtained U.S. Food and Drug Administration (FDA) approval for three products. The company operates with a decentralized hub and spoke model, achieving an average investment per program of less than $40.0 million to proof-of-concept data and less than $10.0 million to reach Investigational New Drug (IND) submission. In addition to its commercial products, led by Attruby, BridgeBio Pharma plans to pursue regulatory submissions for several advanced product candidates, including therapies for achondroplasia, limb-girdle muscular dystrophy type 2I/R9, and autosomal dominant hypocalcemia type 1, all of which have recently released positive Phase 3 data. Since inception, the company has generated 19 investigational new drug applications and contributed to more than 70 peer-reviewed scientific publications. BridgeBio Pharma is a commercial-stage biopharmaceutical company with multiple approved products, a growing global commercial footprint, and a portfolio of late-stage development programs.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 48 items for BBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for BBIO spans 10-Q, 8-K, SCHEDULE 13D/A, 424B7.

Recent high-impact activity:

  • BridgeBio Q3: Revenue Triples to $353M, Loss Narrows to $60M, Cash Reaches $1.5B
  • BridgeBio Q3 Revenue Triples to $353.2M; Three PDUFA Dates in Seven Months
  • Q3 Revenue Triples to $353M as Attruby Climbs; Three PDUFA Dates in Seven Months
  • FDA Grants Priority Review to BridgeBio's Oral Infigratinib for Achondroplasia
  • Acoramidis Cuts Hospitalizations 27% vs Tafamidis in Largest EHR Study

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$502.08M
Net Income
-$732.94M
Diluted EPS
-$3.78
Op. Cash Flow
-$445.91M
Free Cash Flow
-$447.01M
Gross Profit
$481.11M
Operating Income
-$523.41M
Cash & Equivalents
$570.12M
Total Debt
$2.01B
Debt / Equity
-0.96×
Net Margin
-146.0%
Shares Outstanding
194.77M sh
Source: 10-K · filed 2026-02-24 · accession 0001743881-26-000009

Short Interest & Short Volume

7.06 days to cover

FINRA reported short interest of 20,846,164 shares in BBIO as of the October 30, 2026 settlement, a 4.2% increase from the prior period — about 7.1 days to cover at its recent average daily volume. On November 20, 2026, 37.9% of BBIO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)20,846,164 shares as of October 30, 2026
Change vs prior period▲ 4.2%
Days to cover7.06 at avg daily volume of 2,952,343
Daily short volume (FINRA facilities)37.9% of 585,069 shares on November 20, 2026
5-day average short volume70.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for BBIO, detected from its recent SEC filings · based on capital-structure filings through 2026-08-14.

1 recent capital raise1 shelf registration

Secured $933.9 Million in Preferred Equity · Convertible at Significant Premium

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with B →
$76.03
52-week range · as of 2026-10-29 $60.22 – $93.42
Market cap
$14.81B
Volume
1.5M (0.5× avg)
3-mo avg 2.8M
Live data · 2026-11-22 02:23 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BBIO - Latest Insights

BBIO
Oct 29, 2026, 4:52 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.69
Real-time Price: $76.03 info
Change: +$5.34 (+8%) info
Market Cap: $14.811B info
BBIO
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.44
Real-time Price: $76.03 info
Change: +$4.59 (+6%) info
Market Cap: $14.811B info
BBIO
Oct 29, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $70.67
Real-time Price: $76.03 info
Change: +$5.36 (+8%) info
Market Cap: $14.811B info
BBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $65.75
Real-time Price: $76.03 info
Change: +$10.28 (+16%) info
Market Cap: $14.811B info
BBIO
Oct 11, 2026, 2:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $76.03 info
Change: +$10.68 (+16%) info
Market Cap: $14.811B info
BBIO
Oct 11, 2026, 11:42 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $76.03 info
Change: +$10.68 (+16%) info
Market Cap: $14.811B info
BBIO
Oct 06, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $66.39
Real-time Price: $76.03 info
Change: +$9.64 (+15%) info
Market Cap: $14.811B info
BBIO
Oct 05, 2026, 7:40 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $67.98
Real-time Price: $76.03 info
Change: +$8.05 (+12%) info
Market Cap: $14.811B info
BBIO
Sep 23, 2026, 7:47 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $69.50
Real-time Price: $76.03 info
Change: +$6.53 (+9%) info
Market Cap: $14.811B info
BBIO
Sep 09, 2026, 10:33 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $74.79
Real-time Price: $76.03 info
Change: +$1.24 (+2%) info
Market Cap: $14.811B info
BBIO
Sep 09, 2026, 4:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $74.01
Real-time Price: $76.03 info
Change: +$2.02 (+3%) info
Market Cap: $14.811B info
BBIO
Aug 31, 2026, 3:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $77.03
Real-time Price: $76.03 info
Change: -$0.995 (-1%) info
Market Cap: $14.811B info
BBIO
Aug 31, 2026, 3:49 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $76.37
Real-time Price: $76.03 info
Change: -$0.340 (-0.45%) info
Market Cap: $14.811B info
BBIO
Aug 30, 2026, 10:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $76.69
Real-time Price: $76.03 info
Change: -$0.660 (-0.86%) info
Market Cap: $14.811B info
BBIO
Aug 17, 2026, 5:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $80.00
Real-time Price: $76.03 info
Change: -$3.97 (-5%) info
Market Cap: $14.811B info
BBIO
Aug 14, 2026, 6:50 AM EDT
Filing Type: 424B7
Importance Score:
7
Price at Filing: $79.83
Real-time Price: $76.03 info
Change: -$3.80 (-5%) info
Market Cap: $14.811B info
BBIO
Aug 13, 2026, 5:42 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $78.74
Real-time Price: $76.03 info
Change: -$2.71 (-3%) info
Market Cap: $14.811B info
BBIO
Aug 10, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $85.50
Real-time Price: $76.03 info
Change: -$9.47 (-11%) info
Market Cap: $14.811B info
BBIO
Jul 24, 2026, 5:37 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $84.00
Real-time Price: $76.03 info
Change: -$7.97 (-9%) info
Market Cap: $14.811B info
BBIO
Jul 22, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $82.66
Real-time Price: $76.03 info
Change: -$6.63 (-8%) info
Market Cap: $14.811B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets